FIELD: medicine; pharmacology.
SUBSTANCE: antitumoral composition contains taurolipidine, taurultam or their admixture in concentration approximately 0.1-160 mg/ml in combination with biodecomposable adhesive, including the fibrinous hermetic possessing ability to stick to a tissue of a live organism. Invention also concerns a way of processing for the prevention or the inhibition of growth of cancer cells consisting in drawing of an antitumoral composition on certain area of a tissue of a live organism after excising of a tumour. The composition is put on a tissue of an organism by a layer in the thickness from 0.1 to 10 mm.
EFFECT: invention allows preventing with high degree of efficiency repeated development of a tumour after its excising from organism tissues.
18 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING BONE CANCER | 2007 |
|
RU2468796C2 |
| IMPLANTABLE DRUG DELIVERY COMPOSITIONS AND METHODS FOR USING THEM | 2016 |
|
RU2739033C2 |
| COMBINATION OF THERAPEUTICAL AGENTS (FOR EXAMPLE, CHLOROPROMAZINE AND PENTAMIDINE) FOR TREATING NEOPLASTIC DISORDERS | 2001 |
|
RU2286769C2 |
| METHOD FOR TARGETED DELIVERY OF THERAPEUTIC DRUGS TO TUMOR CELLS | 2022 |
|
RU2789807C1 |
| 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE, THERAPEUTIC USES THEREOF | 2013 |
|
RU2659786C2 |
| THERAPEUTIC APPLICATION OF NEW PHARMACEUTICAL PREPARATIONS CONTAINING ANTINEOPLASTIC DRUGS, ASSOCIATED WITH HYALURONIC ACID, IN TREATING NEOPLASMS | 2009 |
|
RU2581972C2 |
| COMBINED THERAPY WITH TYPE II ANTI-CD20 ANTIBODIES IN COMBINATION WITH PROTEASOME INHIBITOR | 2008 |
|
RU2520757C2 |
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
| CEREBRAL CANCER TREATMENT WITH ONCOLYTIC ADENOVIRUS | 2014 |
|
RU2689553C2 |
| THYMIDILATE SYNTHASE TARGETING RNAI MOLECULE AND USING IT | 2010 |
|
RU2535993C2 |
